Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of "Hold" from Brokerages

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been given a consensus recommendation of "Hold" by the eight ratings firms that are covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $17.60.

AMLX has been the subject of a number of recent analyst reports. The Goldman Sachs Group upped their price target on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a "neutral" rating in a research report on Friday, July 12th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of Amylyx Pharmaceuticals in a report on Wednesday, July 10th.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, Director George M. Milne, Jr. purchased 100,000 shares of the business's stock in a transaction on Tuesday, September 3rd. The stock was acquired at an average price of $2.20 per share, for a total transaction of $220,000.00. Following the acquisition, the director now directly owns 858,571 shares of the company's stock, valued at approximately $1,888,856.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.70% of the stock is currently owned by insiders.

Institutional Trading of Amylyx Pharmaceuticals

A number of large investors have recently made changes to their positions in AMLX. AQR Capital Management LLC increased its position in shares of Amylyx Pharmaceuticals by 2,768.0% during the 2nd quarter. AQR Capital Management LLC now owns 3,340,943 shares of the company's stock valued at $6,348,000 after purchasing an additional 3,224,454 shares during the last quarter. Almitas Capital LLC bought a new position in Amylyx Pharmaceuticals during the second quarter valued at $3,617,000. Acadian Asset Management LLC purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at $2,300,000. Farallon Capital Management LLC bought a new stake in shares of Amylyx Pharmaceuticals in the 1st quarter worth about $3,267,000. Finally, Franklin Resources Inc. grew its holdings in Amylyx Pharmaceuticals by 114.4% during the 4th quarter. Franklin Resources Inc. now owns 1,325,001 shares of the company's stock valued at $19,504,000 after purchasing an additional 707,134 shares during the last quarter. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals Stock Down 3.1 %

AMLX traded down $0.08 during trading on Thursday, hitting $2.49. The company's stock had a trading volume of 891,635 shares, compared to its average volume of 2,135,433. The business's 50 day simple moving average is $2.10 and its 200-day simple moving average is $3.17. The firm has a market cap of $169.33 million, a PE ratio of -2.33 and a beta of -0.62. Amylyx Pharmaceuticals has a one year low of $1.58 and a one year high of $20.99.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.35). The company had revenue of ($1.02) million for the quarter, compared to analysts' expectations of $18.83 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. During the same quarter last year, the firm posted $0.31 earnings per share. Equities research analysts expect that Amylyx Pharmaceuticals will post -2.27 EPS for the current fiscal year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.